Meet Ipsen in the US

Welcome, take a look around and learn more about us.

Our mission

To improve patients’ lives

Acting on this mission has propelled us to become a global biopharmaceutical leader with a focus on innovation and specialty care.

Our passion drives our commitment to patients living with difficult-to-treat diseases, and we put them first. Because patients are our priority, we help them through our expertise in oncology, neuroscience, and rare disease.

We bring medicines to patients with the strength of nearly 6,000 employees across the globe, including innovators in our key therapeutic areas.

Download our annual report



Our oncology work focuses on solid tumors and some of the hardest-to-treat cancers. We power a growing portfolio of therapies aimed at improving the lives of patients with gastrointestinal and pancreatic neuroendocrine tumors, carcinoid syndrome, pancreatic cancer, follicular lymphoma and epithelioid sarcoma.


People suffering from neurological disorders are in need of treatments, and we’ve become a global leader in creating them through the research, development, manufacturing and commercialization of neurotoxins to help treat certain types of spasticity in adults and children two years and older, and cervical dystonia in adults.

Rare disease

We continue to evolve and grow our research efforts in the area of rare and ultra-rare disease. Given the limited understanding of these diseases, we are committed to addressing patient needs, from supporting diagnosis to treatment with specific investment in pituitary pathologies, growth disorders, and ultra-rare bone diseases, including fibrodysplasia ossificans progressiva, commonly known as FOP.

Clinical Trials

Clinical trials can lead to medical outcomes that help improve lives, and we thank all of our patients who make this critical research possible through their participation in trials. If you would like to learn more about enrolling in a study, visit

©2022 Ipsen Biopharmaceuticals, Inc. MP-US-000472 June 2022